<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140250" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pentosan Polysulfate Maculopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Margines</surname>
            <given-names>J Ben</given-names>
          </name>
          <aff>University of California Los Angles</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hobbs</surname>
            <given-names>Samuel D.</given-names>
          </name>
          <aff>Wilford Hall Ambulatory Surgical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>J Ben Margines declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samuel Hobbs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140250.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pentosan polysulfate (PPS) is a commonly used medication to treat interstitial cystitis, also known as bladder pain syndrome. PPS was first associated with a progressive retinal pigmentary maculopathy in 2018, a finding&#x000a0;that was later corroborated by several other large studies. PPS maculopathy (PPSM) can cause severe visual impairment by decreasing visual acuity and causing nyctalopia; the condition is generally not reversible and can be progressive. This activity reviews the evaluation, etiology, and diagnostic methodologies to promptly identify PPSM using specialized imaging techniques, shedding light on early recognition and management strategies.</p>
        <p>As&#x000a0;PPS&#x000a0;is the&#x000a0;only FDA-approved medication for interstitial cystitis, its usage spans beyond this indication, including irritable bowel syndrome and pelvic pain syndrome. This course discussion covers&#x000a0;the historical context of PPS, its mechanism of action in urothelial protection, recommended dosages, and its emergence in diverse medical spheres. Considering the evolving understanding of PPSM's pathophysiology and clinical impact, this activity endeavors to equip healthcare professionals with up-to-date knowledge crucial for recognizing and managing this sight-threatening complication associated with PPS usage in interstitial cystitis and other conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify characteristic imaging findings associated with pentosan polysulfate maculopathy (PPSM), such as alterations in fundus autofluorescence and near-infrared reflectance imaging.</p></list-item><list-item><p>Implement standardized screening strategies following accepted guidelines, integrating specialized retinal imaging and comprehensive eye examinations into routine care for patients taking pentosan polysulfate (PPS).</p></list-item><list-item><p>Select appropriate interventions and management approaches based on a comprehensive understanding of PPSM pathophysiology, tailoring treatments to target specific disease mechanisms.</p></list-item><list-item><p>Collaborate with interprofessional healthcare team members&#x000a0;to ensure a coordinated approach to treatment, optimizing the management of PPSM and promoting consistent care across different specialties.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140250&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140250">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140250.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pentosan polysulfate (PPS) is a semisynthetic pentasaccharide heparinoid with anticoagulant properties. It was initially used in the 1950s as a thrombolytic due to the ability of the molecule to bind the glycocalyx of circulating red blood cells.<xref ref-type="bibr" rid="article-140250.r1">[1]</xref><xref ref-type="bibr" rid="article-140250.r2">[2]</xref>&#x000a0;PPS is the only medication approved by the United States Food and Drug Administration to treat interstitial cystitis (IC).<xref ref-type="bibr" rid="article-140250.r3">[3]</xref>&#x000a0;</p>
        <p>IC&#x000a0;is characterized by bladder pain (suprapubic, pelvic, urethral, vaginal, or perineal) caused by filling and relieved by emptying with petechial bladder mucosal hemorrhages on endoscopy and decreased bladder compliance on urodynamics.<xref ref-type="bibr" rid="article-140250.r3">[3]</xref>&#x000a0;This disease is very common,&#x000a0;affecting over&#x000a0;1 million Americans, the vast majority of whom are female.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref>&#x000a0;In the bladder, PPS is postulated to bind to the urothelium and replace disrupted glycosaminoglycans to protect the urothelium.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref>&#x000a0;Less frequently, PPS is used for other indications, including irritable bowel syndrome, pelvic pain syndrome, and inner bladder wall cracks.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref>&#x000a0;The recommended dosage for PPS is 100 mg, 3 times a day.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref></p>
        <p>Twenty-two years after its approval as a second-line agent for interstitial cystitis, a 6-patient case series described a progressive maculopathy associated with long-term use of the drug, an association&#x000a0;that researchers have demonstrated and characterized multiple times.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref><xref ref-type="bibr" rid="article-140250.r6">[6]</xref><xref ref-type="bibr" rid="article-140250.r7">[7]</xref><xref ref-type="bibr" rid="article-140250.r8">[8]</xref><xref ref-type="bibr" rid="article-140250.r9">[9]</xref></p>
      </sec>
      <sec id="article-140250.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Studies agree that the duration of PPS use, which correlates strongly with cumulative exposure to PPS, might be the most important risk factor for developing PPSM.<xref ref-type="bibr" rid="article-140250.r9">[9]</xref><xref ref-type="bibr" rid="article-140250.r10">[10]</xref> Although PPSM has been seen in a patient with only 325 g and 2.25 years of exposure, most patients develop the disease years later.<xref ref-type="bibr" rid="article-140250.r11">[11]</xref> Specifically, a 2022 review averaging&#x000a0;9 studies calculated an average of 15.0 &#x000b1; 5.7 years of exposure and a cumulative exposure of 1824 &#x000b1; 1042 g,&#x000a0;data which were corroborated in a subsequent large review.<xref ref-type="bibr" rid="article-140250.r12">[12]</xref> One of these studies noted a prevalence of toxicity of 16% among all affected patients&#x000a0;versus a prevalence of 40% in those with cumulative dosages greater than 1000 g and 55% in those with a cumulative dose greater than 1500 g.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref></p>
        <p>These studies included patients from&#x000a0;the time of&#x000a0;PPSM diagnosis, not when they become symptomatic, so the onset of the disease is likely earlier.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref> When these patients were categorized by disease severity, there was an association between severity, duration of use, and cumulative dose, but not a daily dose of PPS.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref> This association was also borne out in a large-scale study of insurance records, which showed an increased risk of PPSM among those users with more than&#x000a0;3 years of exposure to PPS compared&#x000a0;with those with less than&#x000a0;3 years (hazard ratio of 9.5 vs 2.2).<xref ref-type="bibr" rid="article-140250.r10">[10]</xref></p>
        <p>The daily dose and dose per unit of body weight are also not infrequently discussed as potential enablers of toxicity. One study found a higher mean daily dose among affected patients (445 vs 302 g).<xref ref-type="bibr" rid="article-140250.r9">[9]</xref> This finding has been corroborated in a survey study in which patients on 100 mg of PPS for 15 years were less likely to report maculopathy than the patients on 500 mg for a median intake of 5 years.<xref ref-type="bibr" rid="article-140250.r13">[13]</xref>&#x000a0;The BMI of affected patients may be on the upper end of normal (24.6 kg/m) but has also been reported to be closer to the middle of the normal range (23.2 kg/m).<xref ref-type="bibr" rid="article-140250.r12">[12]</xref><xref ref-type="bibr" rid="article-140250.r14">[14]</xref></p>
      </sec>
      <sec id="article-140250.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Patients with PPSM are predominantly White (93%) and female (90%), with a mean age of 62.2 &#x000b1; 13.2 years.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref> The prevalence of PPSM among PPS users is difficult to&#x000a0;gauge due to differing study designs, varying durations of drug use, differing cumulative (and perhaps daily) doses, mischaracterization of affected patients as possibly having other maculopathies, and the fact that subtle signs and symptoms of the disease may be missed at a point when rigid screening protocols have not yet been widely adopted.</p>
        <p>Notwithstanding these limitations, the prevalence of PPSM among those who have used PPS ranges&#x000a0;from 0.7%&#x000a0;to 2.4%&#x000a0;and 3.4%&#x000a0;in large-scale retrospective studies from insurance claims databases; however, these studies likely underestimate the true prevalence of PPSM because patients would have to have been diagnosed with another retinal disease, and length of follow-up in the databases limits the ability to find an association between PPS and a retinal disorder.<xref ref-type="bibr" rid="article-140250.r10">[10]</xref><xref ref-type="bibr" rid="article-140250.r14">[14]</xref><xref ref-type="bibr" rid="article-140250.r15">[15]</xref></p>
        <p>Among larger prospective screening studies on known PPS users, the prevalence is estimated to be between 16.5%&#x000a0;and&#x000a0; 23.1%, although these may overestimate the true prevalence because of selection bias.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref><xref ref-type="bibr" rid="article-140250.r8">[8]</xref></p>
      </sec>
      <sec id="article-140250.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>PPS has been proposed to cause this characteristic maculopathy by direct toxicity to either the retinal pigment epithelium (RPE) or the choroid, although other mechanisms have been proposed.&#x000a0;RPE toxicity is thought to be due to PPS interfering with the interaction of the retina's extracellular matrix (ECM) or its regulators, notably fibroblast growth factor (FGF). Choroid toxicity&#x000a0;is postulated due to changes in the choroidal vasculature, specifically the choriocapillaris. These findings are perhaps best supported by imaging, which consistently finds a primary abnormality in these layers, as well as the finding of progression despite drug cessation.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref><xref ref-type="bibr" rid="article-140250.r6">[6]</xref><xref ref-type="bibr" rid="article-140250.r16">[16]</xref></p>
        <p>The ECM in the retina includes the interphotoreceptor matrix (IPM). This area is responsible for intracellular communication, the delivery of signaling molecules, nutrients, and metabolism, maintenance of retina adhesion, photoreceptor alignment, and the transport regulation of oxygen. These processes are&#x000a0;predominantly controlled by the IPM's&#x000a0;large glycosylated proteins, including chondroitin sulfate, dermatan sulfate, SPACR, and SPACRCAN.<xref ref-type="bibr" rid="article-140250.r17">[17]</xref><xref ref-type="bibr" rid="article-140250.r18">[18]</xref><xref ref-type="bibr" rid="article-140250.r19">[19]</xref></p>
        <p>PPS has been shown to interact with cartilage proteoglycans in experimental animal models of arthritis,&#x000a0;leading to its approval&#x000a0;as a disease-modifying antirheumatic agent for veterinarians.<xref ref-type="bibr" rid="article-140250.r2">[2]</xref> In infectious arthritis, PPS&#x000a0;has been shown to be associated with decreased levels of ADAMTs5 and TIMP-3 and stable levels of aggrecan, collagen I, and II.<xref ref-type="bibr" rid="article-140250.r2">[2]</xref>&#x000a0;The ECM and IPM also contain complement factor H<xref ref-type="bibr" rid="article-140250.r18">[18]</xref>; PPS has been shown to inhibit the alternative and classical pathways of complement activation and could have a harmful effect via this pathway as well.<xref ref-type="bibr" rid="article-140250.r2">[2]</xref> Due to its structural similarity to these glycosylated proteins, PPS could displace the normal IPM constituents, similar to its effect in the bladder urothelium.</p>
        <p>One additional component of the ECM and IPM is the fibroblast growth factors (FGFs)&#x000a0;that bind to heparin and heparan sulfate.<xref ref-type="bibr" rid="article-140250.r20">[20]</xref> PPS has been shown to inhibit the FGF-1, -2, and -4 signaling pathways, which play an important role in animal models of the organization and development of the retina, as well as maintenance of retinal health and regeneration.<xref ref-type="bibr" rid="article-140250.r21">[21]</xref></p>
        <p>When FGF signaling is inhibited in transgenic zebrafish, the RPE layer thickens significantly as the cells grow to contact the outer segments of the photoreceptors.<xref ref-type="bibr" rid="article-140250.r22">[22]</xref> In humans, certain chemotherapeutic agents target FGF receptors (FGFRs), including erdafitinib (pan-FGFR inhibitor) and pemigatinib (FGFR 1-3), both of which&#x000a0;have been shown to induce an increase in reflectivity and thickening of the ellipsoid and interdigitation zones, with subsequent subretinal fluid (SRF) and serous retinal detachment.<xref ref-type="bibr" rid="article-140250.r23">[23]</xref><xref ref-type="bibr" rid="article-140250.r24">[24]</xref><xref ref-type="bibr" rid="article-140250.r25">[25]</xref><xref ref-type="bibr" rid="article-140250.r26">[26]</xref>&#x000a0;SRF from chemotherapeutic targeting starts an average of 21 days after starting&#x000a0;the medication.&#x000a0;Conversely, SRF will often resolve without discontinuation of PPS. Additionally,&#x000a0;in one case report, there were no changes to the choroidal vasculature&#x000a0;<xref ref-type="bibr" rid="article-140250.r24">[24]</xref><xref ref-type="bibr" rid="article-140250.r27">[27]</xref></p>
        <p>More recent research using optical coherence tomography&#x02013;angiography (OCT-A) to characterize choroidal vasculature in PPS-exposed patients who have no other findings of PPSM has shown increased vascular flow deficits within the choriocapillaris and decreased choroidal stroma in the deeper Haller and Sattler layers, leading to an increased choroidal vascular index (CVI). (CVI corresponds to the ratio between the choroidal luminal area and the luminal&#x000a0;and stromal areas.) As the authors point out, this could be due to the choriocapillaris being a secondary target of PPSM or a secondary effect of the disrupted RPE.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref><xref ref-type="bibr" rid="article-140250.r28">[28]</xref>&#x000a0;</p>
        <p>The fact that these flow voids are detectable in patients without other stigmata of the disease lends credence to the choriocapillaris being a primary site of injury, as ischemic changes would only be expected to progress. Further, the evidence that visual acuity is spared despite these changes in the choriocapillaris flow may also support this argument.<xref ref-type="bibr" rid="article-140250.r7">[7]</xref></p>
        <p>Other proposals for the pathogenesis of PPSM include mitochondrial dysfunction (based on phenotypic similarity)&#x000a0;and the fact that there may be an undefined common cause of interstitial cystitis, making the maculopathy unrelated to PPS exposure.<xref ref-type="bibr" rid="article-140250.r1">[1]</xref><xref ref-type="bibr" rid="article-140250.r29">[29]</xref><xref ref-type="bibr" rid="article-140250.r30">[30]</xref></p>
        <p>In sum, the ECM of the RPE and the choroidal vasculature contain numerous constituents that have either been shown to be affected by PPS or have theoretical interactions based on the structure of PPS. Therefore, the pathogenesis of PPSM is likely located in this area.<xref ref-type="bibr" rid="article-140250.r21">[21]</xref></p>
      </sec>
      <sec id="article-140250.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with PPSM will report a history of chronic use of PPS, which they may have already discontinued. If they are unable to report the use of the medication, they may also report having used a drug to help with bladder pain.</p>
        <p>Although patients can be asymptomatic, they may also present with the following symptoms in order of decreasing frequency: decreased visual acuity, nyctalopia, metamorphopsia, paracentral scotoma, and delayed dark adaptation.<xref ref-type="bibr" rid="article-140250.r7">[7]</xref><xref ref-type="bibr" rid="article-140250.r11">[11]</xref>&#x000a0;These symptoms are generally accepted as having a gradual onset. However, one case report described a patient who transitioned from asymptomatic and without retinal findings to having developed advanced PPSM within&#x000a0;2 years.<xref ref-type="bibr" rid="article-140250.r31">[31]</xref></p>
        <p>Regarding visual acuity, the decrease experienced by patients is typically mild, with many studies reporting an average of 20/25 unless the patchy areas of the atrophic retina coalesce into the central fovea.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref><xref ref-type="bibr" rid="article-140250.r5">[5]</xref><xref ref-type="bibr" rid="article-140250.r32">[32]</xref> However, measures of visual acuity alone fail to characterize the visual disability caused by PPSM. Patient-reported outcomes on the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-39) reflect that patients with moderate and advanced PPSM have worse function than those with intermediate age-related macular degeneration (AMD). Additionally,&#x000a0;results on the Low Luminance Questionnaire reflect especially low subjective scores on driving, dim lighting, and extreme lighting.<xref ref-type="bibr" rid="article-140250.r32">[32]</xref></p>
        <p>Delayed dark adaptation&#x000a0;has also been studied objectively. Although many patients were found to have an increased rod intercept time, the wide variability of the results caused the test to have a low sensitivity for detecting PPSM.<xref ref-type="bibr" rid="article-140250.r32">[32]</xref></p>
        <p>Patients are unaffected by decreased contrast sensitivity until late in the disease state.<xref ref-type="bibr" rid="article-140250.r32">[32]</xref></p>
      </sec>
      <sec id="article-140250.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Anterior segment examination is predominantly within normal limits for patients of this age.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref> Fundus examination findings can be subtle and are primarily characterized as densely-packed bilateral paracentral hyperpigmented spots with surrounding yellow subretinal deposits with mottled RPE atrophy.<xref ref-type="bibr" rid="article-140250.r11">[11]</xref><xref ref-type="bibr" rid="article-140250.r33">[33]</xref> Most of these spots are bilateral (97.3%) and confined to the posterior pole; however, wide-field imaging has also shown that 36% of patients had changes in the peripheral retina.<xref ref-type="bibr" rid="article-140250.r6">[6]</xref><xref ref-type="bibr" rid="article-140250.r12">[12]</xref><xref ref-type="bibr" rid="article-140250.r6">[6]</xref></p>
        <p>The pattern is most striking on autofluorescence, which shows a typically well-circumscribed area of small, densely-packed hyper- and hypoautofluorescent spots.<xref ref-type="bibr" rid="article-140250.r11">[11]</xref><xref ref-type="bibr" rid="article-140250.r34">[34]</xref> Fundus autofluorescence (FAF) also discloses that 100% of eyes have a peripapillary hypoautofluorescent halo.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref></p>
        <p>On OCT, the colocalized yellowish pigment on fundus examination and the hyperautofluorescent lesions correspond to nodular RPE abnormalities and excrescences, which cast a shadow onto the underlying choroid (thereby differentiating them from drusen).<xref ref-type="bibr" rid="article-140250.r4">[4]</xref><xref ref-type="bibr" rid="article-140250.r11">[11]</xref> With time, these areas of excrescences and conglomerations change; specifically, overlying retinal layers will progressively thin, and there will be associated RPE atrophy.<xref ref-type="bibr" rid="article-140250.r6">[6]</xref><xref ref-type="bibr" rid="article-140250.r7">[7]</xref><xref ref-type="bibr" rid="article-140250.r8">[8]</xref><xref ref-type="bibr" rid="article-140250.r11">[11]</xref> Cystoid macular edema (CME) occurs less frequently (between 4.2% and 12.9% of patients),&#x000a0;as do neovascular membranes (1.4% to 17.6% of patients)&#x000a0;and subfoveal vitelliform deposits.<xref ref-type="bibr" rid="article-140250.r35">[35]</xref></p>
        <p>Near-infrared reflectance (NIR), co-acquired with OCT, is often highly effective in showing the characteristic lesions in mild forms of the disease, including when FAF findings are inconclusive.<xref ref-type="bibr" rid="article-140250.r12">[12]</xref>&#x000a0;Specifically, similar symmetrical hyperreflectant spots centered on the macula may be seen on NIR,&#x000a0;whereas the FAF does not show these lesions. This difference may be due to NIR utilizing a longer wavelength of light (820 nm) than FAF (480 nm), penetrating more avidly into deeper retinal layers.<xref ref-type="bibr" rid="article-140250.r36">[36]</xref> The critical implication of this finding is that patients who are unable to access a center with fundus autofluorescence capabilities can still be screened if OCT is used.</p>
        <p>On OCT-A, PPSM has many characteristic findings that may hint at the ultimate pathophysiology of the disease. PPSM is associated with abnormal foveal avascular zone (FAZ) configurations and decreased choriocapillaris perfusion in patients with later stages of the disease. These areas of decreased perfusion were shown to have a flow void average of 54%, compared&#x000a0;with 14% in non-PPSM patients, and they correspond to areas of outer retinal atrophy.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref><xref ref-type="bibr" rid="article-140250.r7">[7]</xref></p>
        <p>A separate analysis of the stroma on OCT-A found a decreased stromal choroidal area with a preserved stromal luminal area, yielding an increased choroidal vascularity index.&#x000a0;These changes on OCT-A may be utilized to detect patients with forme fruste PPSM, as increased flow voids were found in 15 patients with greater than 1000 g of PPS exposure who had no other findings on retinal imaging.<xref ref-type="bibr" rid="article-140250.r28">[28]</xref> Further, it can help differentiate the condition from AMD, in which the choroidal vascularity index increases.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref> Importantly, OCT-A can also identify patients with choroidal neovascular membranes.<xref ref-type="bibr" rid="article-140250.r12">[12]</xref><xref ref-type="bibr" rid="article-140250.r37">[37]</xref></p>
        <p>When tested on electroretinography (ERG), patients can have nonspecific responses ranging from normal&#x000a0;to mild attenuation of amplitude in code and rod responses&#x000a0;with variable delay in response.<xref ref-type="bibr" rid="article-140250.r38">[38]</xref> Similarly, multifocal ERG will reflect mild-to-severe attenuation of response amplitude.<xref ref-type="bibr" rid="article-140250.r6">[6]</xref><xref ref-type="bibr" rid="article-140250.r34">[34]</xref> Electro-oculograms reflect predominantly normal Arden ratios, though dark adaptometry is frequently found to be prolonged.<xref ref-type="bibr" rid="article-140250.r7">[7]</xref><xref ref-type="bibr" rid="article-140250.r11">[11]</xref><xref ref-type="bibr" rid="article-140250.r32">[32]</xref></p>
        <p>Multiple studies have included genetic testing for patients with PPSM to rule out other maculopathies.&#x000a0;Although none have found clear associations, some wonder if there may be a genetic predisposition to having a more severe phenotype.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref><xref ref-type="bibr" rid="article-140250.r7">[7]</xref><xref ref-type="bibr" rid="article-140250.r39">[39]</xref>&#x000a0;For example, a patient in one study had an <italic toggle="yes">NPHP1</italic> mutation and severe phenotype, and another had a family history of&#x000a0;AMD and a variant of undetermined significance in the <italic toggle="yes">RP1</italic> gene who presented with geographic atrophy and count fingers vision.<xref ref-type="bibr" rid="article-140250.r7">[7]</xref><xref ref-type="bibr" rid="article-140250.r9">[9]</xref> Other studies have reported multiple variants of uncertain significance, including <italic toggle="yes">ABCA4</italic>, <italic toggle="yes">ADAM9</italic>, <italic toggle="yes">IMPG2</italic>, <italic toggle="yes">MPZ</italic>, and <italic toggle="yes">TIMP3</italic>.<xref ref-type="bibr" rid="article-140250.r6">[6]</xref></p>
        <p>Based on these results, Barnes and colleagues proposed&#x000a0;6 diagnostic criteria:<xref ref-type="bibr" rid="article-140250.r33">[33]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Macular hyperpigmented spots with yellow-orange deposits and patchy RPE atrophy on fundus photography</p>
          </list-item>
          <list-item>
            <p>Densely packed clusters of hyper- and hypoautofluorescent areas within the posterior pole on FAF</p>
          </list-item>
          <list-item>
            <p>Focal thickening of the RPE with hyperreflectance on NIR</p>
          </list-item>
          <list-item>
            <p>The peripapillary hypoautofluorescent halo</p>
          </list-item>
          <list-item>
            <p>Maximum size of the hyperautofluorescent spots of 2 venule widths.</p>
          </list-item>
          <list-item>
            <p>Absence of typical drusen</p>
          </list-item>
        </list>
        <p>Further, based on their work, Wang and colleagues proposed the following guidelines for defining disease severity:<xref ref-type="bibr" rid="article-140250.r9">[9]</xref></p>
        <list list-type="order">
          <list-item>
            <p><bold>Mild:</bold> Speckled pattern on FAF without well-demarcated atrophic lesions on FAF and no evidence of complete RPE and outer retinal atrophy</p>
          </list-item>
          <list-item>
            <p><bold>Moderate:</bold>&#x000a0;Well-demarcated, nummular, and colocalized lesions with RPE and outer retinal atrophy; no central foveal involvement</p>
          </list-item>
          <list-item>
            <p><bold>Severe:</bold> Well-demarcated lesions with associated hypoautofluorescent atrophy with RPE and outer retinal atrophy, which involves the central fovea</p>
          </list-item>
        </list>
        <p>Hanif and colleagues proposed a similar classification of severity:<xref ref-type="bibr" rid="article-140250.r6">[6]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Disease within the vascular arcades and without areas of atrophy</p>
          </list-item>
          <list-item>
            <p>Disease extending to the vascular arcades but not more than 2&#x000a0; disc diameters beyond or the presence of noncentral atrophy.</p>
          </list-item>
          <list-item>
            <p>Disease that extends more than 2&#x000a0; disc diameters beyond the temporal arcades or the presence of central foveal atrophy.</p>
          </list-item>
        </list>
        <p>Additionally, Wang et al found a&#x000a0;correlation between disease severity and cumulative dosage; however, the sample size was too small to&#x000a0;draw&#x000a0;any conclusions.<xref ref-type="bibr" rid="article-140250.r5">[5]</xref></p>
      </sec>
      <sec id="article-140250.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no known treatment for PPSM; therefore, primary prevention is imperative with medication avoidance or using the lowest effective dose if necessary. The sight-threatening sequelae of PPSM can be treated with common medications already used to address those conditions. For example, patients with cystoid macular edema have been successfully treated with carbonic anhydrase inhibitors and anti&#x02013;vascular endothelial growth factor (VEGF) drugs, and patients with choroidal neovascular membranes have been treated with intravitreal anti-VEGF medications.<xref ref-type="bibr" rid="article-140250.r37">[37]</xref></p>
      </sec>
      <sec id="article-140250.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of PPSM and the primary methods of differentiating it from these conditions include:</p>
        <p>
<bold>AMD</bold>
</p>
        <p>PPSM and AMD are characterized by patients with similar demographics and pigmentary macular changes, which can progress to geographic atrophy. The&#x000a0;2 entities can be differentiated via multimodal imaging and identification of the typical pattern of PPSM.<xref ref-type="bibr" rid="article-140250.r40">[40]</xref></p>
        <p>Specifically, hyperpigmented macular spots with yellow-orange deposits, which are at the level of the RPE and not below, along with dense packing of hyper- and hypoautofluorescent spots on FAF&#x000a0;(especially with a peripapillary autofluorescent halo) best describe PPSM. On the other hand, AMD can be identified by drusen, which is below the RPE. In one study comparing these diagnoses, no macular drusen were found in eyes diagnosed with PPS. In contrast, RPEE pigmentary clumps were more frequently found in AMD eyes of patients with prior PPS exposure.<xref ref-type="bibr" rid="article-140250.r40">[40]</xref>&#x000a0;</p>
        <p>
<bold>Pattern Dystrophy</bold>
</p>
        <p>When differentiating PPSM from other pattern dystrophies, the same framework from above is used; however, special attention is paid to three features in patients with borderline imaging.<xref ref-type="bibr" rid="article-140250.r33">[33]</xref> First, the peripapillary hypoautofluorescent halo is extremely useful for differentiating from the <italic toggle="yes">ABCA4</italic>-retinopathies; however, it is less so when the disease has not yet progressed to encompassing the optic nerve. Second, the density of abnormalities in PPSM is significantly higher than what is seen in hereditary maculopathies. Third, PPSM can involve (but does not necessarily have to) the central fovea early in the disease course.<xref ref-type="bibr" rid="article-140250.r33">[33]</xref></p>
        <p>Inquiring about the family history or performing genetic testing can be useful in cases that are not elucidated by these three findings.</p>
        <p>
<bold>Mitochondrial Dystrophy</bold>
</p>
        <p>There is a phenotypic overlap between PPSM and mitochondrial retinopathies, including reticulated-appearing fundus, peripapillary atrophy, and nyctalopia. One difference that may be seen between these diseases is that PPSM does not necessarily spare the fovea early in the disease, whereas mitochondrial illnesses will. Further, mitochondrial illnesses often have systemic manifestations not seen in PPSM, such as muscle weakness (eg, cardiomyopathy).<xref ref-type="bibr" rid="article-140250.r41">[41]</xref></p>
      </sec>
      <sec id="article-140250.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>PPSM is a progressive maculopathy that leads to areas of RPE atrophy&#x000a0;that can decrease visual acuity, causing legal blindness. Other visually debilitating symptoms&#x000a0;include nyctalopia, metamorphopsia, a paracentral scotoma, and delayed dark adaptation.<xref ref-type="bibr" rid="article-140250.r4">[4]</xref> The disease may progress despite discontinuation; however, cessation may help slow or reverse the disease.<xref ref-type="bibr" rid="article-140250.r7">[7]</xref><xref ref-type="bibr" rid="article-140250.r42">[42]</xref><xref ref-type="bibr" rid="article-140250.r43">[43]</xref><xref ref-type="bibr" rid="article-140250.r44">[44]</xref><xref ref-type="bibr" rid="article-140250.r45">[45]</xref></p>
      </sec>
      <sec id="article-140250.s11" sec-type="Complications">
        <title>Complications</title>
        <p>In addition to decreased visual acuity from RPE atrophy, the sight-threatening sequelae of PPSM include CME,&#x000a0;subfoveal vitelliform deposits,&#x000a0;and macular neovascular membranes.<xref ref-type="bibr" rid="article-140250.r12">[12]</xref><xref ref-type="bibr" rid="article-140250.r35">[35]</xref><xref ref-type="bibr" rid="article-140250.r37">[37]</xref><xref ref-type="bibr" rid="article-140250.r46">[46]</xref></p>
      </sec>
      <sec id="article-140250.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>In addition to educating urologists and urogynecologists on PPSM, various proposals for screening guidelines for&#x000a0;the condition have been proposed.&#x000a0;All generally agree on baseline testing at the initiation of treatment with PPS, annual testing after that, and collaborative decision-making about drug discontinuation when patients have a cumulative dose of greater than 1500 g. At each screening appointment with the ophthalmologist, various imaging modalities should be used, including NIR, FAF, and OCT-A, if possible.<xref ref-type="bibr" rid="article-140250.r28">[28]</xref><xref ref-type="bibr" rid="article-140250.r47">[47]</xref>&#x000a0;The need to screen patients has successfully been integrated into an electronic medical record system at a single institution.<xref ref-type="bibr" rid="article-140250.r48">[48]</xref></p>
      </sec>
      <sec id="article-140250.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although no large-scale interventional studies to discontinue PPS have been conducted, experts agree that communication between urologists, urogynecologists, and ophthalmologists should be codified to screen PPS patients continuously.<xref ref-type="bibr" rid="article-140250.r47">[47]</xref>&#x000a0;Pharmacists also play a crucial&#x000a0;role in patient education on the drug and its proper use, monitoring, and dosing. They can coordinate with nursing staff as part of an interprofessional ophthalmological care team.</p>
      </sec>
      <sec id="article-140250.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140250&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140250">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/pentosan-polysulfate-maculopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=140250">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140250/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140250">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-140250.s15">
        <fig id="article-140250.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Mild pentosan polysulfate maculopathy of the right eye as imaged with false color and fundus autofluorescence. Note the trace speckled pigmentary changes. Used with permission from David Sarraf, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__1__-__Mild__PPS__OD__Color__and__FAF" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140250.s16">
        <fig id="article-140250.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Moderate pentosan polysulfate maculopathy of the right eye as imaged with false color and fundus autofluorescence. Note the striking speckled pigmentary changes. Used with permission from David Sarraf, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__3__-__Moderate__PPS__OD__Color__and__FAF" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140250.s17">
        <fig id="article-140250.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Moderate pentosan polysulfate maculopathy of the right eye as imaged with optical coherence tomography. Node the nodular RPE excrescences which cast a shadow onto the underlying choroid with associated areas of complete RPE and outer retinal atrophy. Used with permission from David Sarraf, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__4__-__Mod__PPS__OD__OCT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140250.s18">
        <fig id="article-140250.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Mild pentosan polysulfate maculopathy without imaging findings on color fundus photography, fundus autofluorescence, or optical coherence tomography is seen here on OCT-Angiography as increased flow deficits (examples highlighted in orange), lending a moth-eaten appearance. Used with permission from David Sarraf, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__5__-__Mild__PPS__OCT-A__Choriocapillaris" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140250.s19">
        <fig id="article-140250.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Mild pentosan polysulfate maculopathy as imaged on near infrared reflectance. Notice that the speckled pigmentary changes which were extremely subtle on false color and fundus autofluorescence are more easily seen in the parafoveal macula Used with permission from David Sarraf, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__2__-__Mild__PPS__OD__NIR" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-140250.s20">
        <title>References</title>
        <ref id="article-140250.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paredes Mogica</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>De</surname>
                <given-names>EJB</given-names>
              </name>
            </person-group>
            <article-title>Pentosan Polysulfate Maculopathy: What Urologists Should Know in 2020.</article-title>
            <source>Urology</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>147</volume>
            <fpage>109</fpage>
            <page-range>109-118</page-range>
            <pub-id pub-id-type="pmid">33045286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herrero</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Foo</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Forwood</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bucala</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahalingam</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pentosan Polysulfate: a Novel Glycosaminoglycan-Like Molecule for Effective Treatment of Alphavirus-Induced Cartilage Destruction and Inflammatory Disease.</article-title>
            <source>J Virol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>89</volume>
            <issue>15</issue>
            <fpage>8063</fpage>
            <page-range>8063-76</page-range>
            <pub-id pub-id-type="pmid">26018160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Moldwin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>FDA BRUDAC 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for Research.</article-title>
            <source>J Urol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>200</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-42</page-range>
            <pub-id pub-id-type="pmid">29452126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindeke-Myers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanif</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pentosan polysulfate maculopathy.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2022</year>
            <season>Jan-Feb</season>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-96</page-range>
            <pub-id pub-id-type="pmid">34000253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Velaga</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Grondin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nittala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chhablani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vupparaboina</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Gunnemann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ip</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sadda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarraf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pentosan Polysulfate Maculopathy: Prevalence, Spectrum of Disease, and Choroidal Imaging Analysis Based on Prospective Screening.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>227</volume>
            <fpage>125</fpage>
            <page-range>125-138</page-range>
            <pub-id pub-id-type="pmid">33651989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanif</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Armenti</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Igelman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Jayasundera</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Pennesi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Khurana</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Foote</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>O'Keefe</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Flaxel</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy: A Multicenter Study.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>137</volume>
            <issue>11</issue>
            <fpage>1275</fpage>
            <page-range>1275-1282</page-range>
            <pub-id pub-id-type="pmid">31486843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abou-Jaoude</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Leys</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hinkle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Odom</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>New Insights Into Pentosan Polysulfate Maculopathy.</article-title>
            <source>Ophthalmic Surg Lasers Imaging Retina</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-22</page-range>
            <pub-id pub-id-type="pmid">33471910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vora</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Melles</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Maculopathy Associated with Long-Term Pentosan Polysulfate Therapy.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>127</volume>
            <issue>6</issue>
            <fpage>835</fpage>
            <page-range>835-836</page-range>
            <pub-id pub-id-type="pmid">32085877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gunnemann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hilely</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scharf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sarraf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-125</page-range>
            <pub-id pub-id-type="pmid">31973791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bae</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sodhi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maberley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kezouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Etminan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk of maculopathy with pentosan polysulfate sodium use.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>88</volume>
            <issue>7</issue>
            <fpage>3428</fpage>
            <page-range>3428-3433</page-range>
            <pub-id pub-id-type="pmid">35277990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abou-Jaoude</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Update on maculopathy secondary to pentosan polysulfate toxicity.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>233</fpage>
            <page-range>233-239</page-range>
            <pub-id pub-id-type="pmid">33710012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Wykoff</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>NJS</given-names>
              </name>
              <name>
                <surname>Khurana</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Zacks</surname>
                <given-names>DN</given-names>
              </name>
              <collab>Macula Society Pentosan Polysulfate Maculopathy Study Group</collab>
            </person-group>
            <article-title>Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study.</article-title>
            <source>Ophthalmol Retina</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-227</page-range>
            <pub-id pub-id-type="pmid">34298229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uner</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>PENTOSAN POLYSULFATE AND VISION: Findings from an International Survey of Exposed Individuals.</article-title>
            <source>Retina</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>1562</fpage>
            <page-range>1562-1569</page-range>
            <pub-id pub-id-type="pmid">33332810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ludwig</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Vail</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Callaway</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Pasricha</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Moshfeghi</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>535</fpage>
            <page-range>535-543</page-range>
            <pub-id pub-id-type="pmid">31899034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>VanderBeek</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>104</volume>
            <issue>8</issue>
            <fpage>1093</fpage>
            <page-range>1093-1097</page-range>
            <pub-id pub-id-type="pmid">31694837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simonett</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Pennesi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>138</volume>
            <issue>8</issue>
            <fpage>894</fpage>
            <page-range>894-900</page-range>
            <pub-id pub-id-type="pmid">32644147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Charbel Issa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Birtel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bergholz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dahlke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zobor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>BHF</given-names>
              </name>
              <name>
                <surname>St&#x000f6;hr</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans, IMPG1 and IMPG2, in Patients with Vitelliform Macular Lesions.</article-title>
            <source>Genes (Basel)</source>
            <year>2017</year>
            <month>Jun</month>
            <day>23</day>
            <volume>8</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">28644393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishikawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshitomi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Structure and function of the interphotoreceptor matrix surrounding retinal photoreceptor cells.</article-title>
            <source>Exp Eye Res</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>133</volume>
            <fpage>3</fpage>
            <page-range>3-18</page-range>
            <pub-id pub-id-type="pmid">25819450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Keenan</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Fielder</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Collinson</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Holley</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Merry</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>van Kuppevelt</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2011</year>
            <month>Aug</month>
            <day>17</day>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>6511</fpage>
            <page-range>6511-21</page-range>
            <pub-id pub-id-type="pmid">21746802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burgess</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Maciag</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The heparin-binding (fibroblast) growth factor family of proteins.</article-title>
            <source>Annu Rev Biochem</source>
            <year>1989</year>
            <volume>58</volume>
            <fpage>575</fpage>
            <page-range>575-606</page-range>
            <pub-id pub-id-type="pmid">2549857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenlee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hom</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Babiuch</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Re: Pearce et&#x000a0;al.: Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium (Ophthalmology. 2018;125:1793-1802).</article-title>
            <source>Ophthalmology</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>126</volume>
            <issue>7</issue>
            <fpage>e51</fpage>
            <pub-id pub-id-type="pmid">31229012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hochmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaslin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Machate</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geffarth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Funk</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fgf signaling is required for photoreceptor maintenance in the adult zebrafish retina.</article-title>
            <source>PLoS One</source>
            <year>2012</year>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>e30365</fpage>
            <pub-id pub-id-type="pmid">22291943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bloom</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Edakkunnathu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kondapalli</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Transient pemigatinib-induced subretinal fluid accumulation and serous retinal detachment.</article-title>
            <source>Clin Exp Optom</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>106</volume>
            <issue>5</issue>
            <fpage>560</fpage>
            <page-range>560-563</page-range>
            <pub-id pub-id-type="pmid">35793865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fasolino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moschetta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Gr&#x000e8;ve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nelis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lefesvre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ten Tusscher</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2022</year>
            <month>Jan</month>
            <day>20</day>
            <volume>12</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35204340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eliott</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>138</volume>
            <issue>10</issue>
            <fpage>1101</fpage>
            <page-range>1101-1103</page-range>
            <pub-id pub-id-type="pmid">32789485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Camacci</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bowie</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor.</article-title>
            <source>Case Rep Ophthalmol</source>
            <year>2022</year>
            <season>Jan-Apr</season>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">35350233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francis</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Schram</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Canestraro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haggag-Lindgren</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heinemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kriplani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jhaveri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Bajorin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abou-Alfa</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Drilon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>139</volume>
            <issue>10</issue>
            <fpage>1126</fpage>
            <page-range>1126-1130</page-range>
            <pub-id pub-id-type="pmid">34473206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fogel Levin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Santina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corradetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Somisetty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Romero Morales</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sadda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarraf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pentosan Polysulfate Sodium-Associated Maculopathy: Early Detection Using OCT Angiography and Choriocapillaris Flow Deficit Analysis.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>244</volume>
            <fpage>38</fpage>
            <page-range>38-47</page-range>
            <pub-id pub-id-type="pmid">35901995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yusuf</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Charbel Issa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lotery</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Pentosan Polysulfate Maculopathy-Prescribers Should Be Aware.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>138</volume>
            <issue>8</issue>
            <fpage>900</fpage>
            <page-range>900-902</page-range>
            <pub-id pub-id-type="pmid">32644128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Re: Pentosan Polysulfate Maculopathy: What Urologists Should Know in 2020.</article-title>
            <source>Urology</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>152</volume>
            <fpage>205</fpage>
            <page-range>205-206</page-range>
            <pub-id pub-id-type="pmid">33493509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somisetty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Sarraf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>RAPID PENTOSAN POLYSULFATE SODIUM MACULOPATHY PROGRESSION.</article-title>
            <source>Retin Cases Brief Rep</source>
            <year>2023</year>
            <month>Nov</month>
            <day>01</day>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>660</fpage>
            <page-range>660-663</page-range>
            <pub-id pub-id-type="pmid">35385434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyons</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Brower</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Visual Function in Pentosan Polysulfate Sodium Maculopathy.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2020</year>
            <month>Nov</month>
            <day>02</day>
            <volume>61</volume>
            <issue>13</issue>
            <fpage>33</fpage>
            <pub-id pub-id-type="pmid">33231621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hanif</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pentosan Polysulfate Maculopathy versus Inherited Macular Dystrophies: Comparative Assessment with Multimodal Imaging.</article-title>
            <source>Ophthalmol Retina</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>12</issue>
            <fpage>1196</fpage>
            <page-range>1196-1201</page-range>
            <pub-id pub-id-type="pmid">32446908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearce</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium.</article-title>
            <source>Ophthalmology</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>125</volume>
            <issue>11</issue>
            <fpage>1793</fpage>
            <page-range>1793-1802</page-range>
            <pub-id pub-id-type="pmid">29801663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wannamaker</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Sisk</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Large Subfoveal Vitelliform Lesions in a Case of Pentosan Polysulfate Maculopathy.</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>127</volume>
            <issue>12</issue>
            <fpage>1641</fpage>
            <pub-id pub-id-type="pmid">33222775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdolrahimzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ciancimino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grassi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sordi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fragiotta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scuderi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Near-Infrared Reflectance Imaging in Retinal Diseases Affecting Young Patients.</article-title>
            <source>J Ophthalmol</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>5581851</fpage>
            <pub-id pub-id-type="pmid">34373789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mishra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Choroidal Neovascularization Associated with Pentosan Polysulfate Toxicity.</article-title>
            <source>Ophthalmol Retina</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-113</page-range>
            <pub-id pub-id-type="pmid">31570285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vora</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Melles</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A case of pentosan polysulfate maculopathy originally diagnosed as stargardt disease.</article-title>
            <source>Am J Ophthalmol Case Rep</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>17</volume>
            <fpage>100604</fpage>
            <pub-id pub-id-type="pmid">32043016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalaw</surname>
                <given-names>FGP</given-names>
              </name>
              <name>
                <surname>Ignacio</surname>
                <given-names>JCI</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Ferreyra</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nudleman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Borooah</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>PENTOSAN POLYSULFATE SODIUM (ELMIRON) MACULOPATHY: A Genetic Perspective.</article-title>
            <source>Retina</source>
            <year>2023</year>
            <month>Jul</month>
            <day>01</day>
            <volume>43</volume>
            <issue>7</issue>
            <fpage>1174</fpage>
            <page-range>1174-1181</page-range>
            <pub-id pub-id-type="pmid">36996461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christiansen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pentosan polysulfate maculopathy versus age-related macular degeneration: comparative assessment with multimodal imaging.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-22</page-range>
            <pub-id pub-id-type="pmid">33722504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanif</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pattern Dystrophy: An Imprecise Diagnosis in the Age of Precision Medicine.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2019</year>
            <season>Winter</season>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>173</fpage>
            <page-range>173-194</page-range>
            <pub-id pub-id-type="pmid">30585925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnett</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>POTENTIAL NEW-ONSET CLINICALLY DETECTABLE PENTOSAN POLYSULFATE MACULOPATHY YEARS AFTER DRUG CESSATION.</article-title>
            <source>Retin Cases Brief Rep</source>
            <year>2022</year>
            <month>Nov</month>
            <day>01</day>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>724</fpage>
            <page-range>724-726</page-range>
            <pub-id pub-id-type="pmid">33229920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Higgins</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bacorn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rothschild</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Moshiri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Identification of Patients with Pentosan Polysulfate Sodium-Associated Maculopathy through Screening of the Electronic Medical Record at an Academic Center.</article-title>
            <source>J Ophthalmol</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>8866961</fpage>
            <pub-id pub-id-type="pmid">33489347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huckfeldt</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Vavvas</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium.</article-title>
            <source>Ophthalmic Surg Lasers Imaging Retina</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>50</volume>
            <issue>10</issue>
            <fpage>656</fpage>
            <page-range>656-659</page-range>
            <pub-id pub-id-type="pmid">31671200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Lindeke-Myers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate Use.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2023</year>
            <month>Mar</month>
            <day>01</day>
            <volume>141</volume>
            <issue>3</issue>
            <fpage>260</fpage>
            <page-range>260-266</page-range>
            <pub-id pub-id-type="pmid">36729449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dieu</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Whittier</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Domalpally</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pak</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Voland</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Crabtree</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>McAchran</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Mititelu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Redefining the Spectrum of Pentosan Polysulfate Retinopathy: Multimodal Imaging Findings from a Cross-Sectional Screening Study.</article-title>
            <source>Ophthalmol Retina</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>835</fpage>
            <page-range>835-846</page-range>
            <pub-id pub-id-type="pmid">35339727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadda</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>A path to the development of screening guidelines for pentosan maculopathy.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-2</page-range>
            <pub-id pub-id-type="pmid">32085858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140250.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hom</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sastry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Muste</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Characterization of pentosan polysulfate patients for development of an alert and screening system for ophthalmic monitoring.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-136</page-range>
            <pub-id pub-id-type="pmid">36878265</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
